Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) (Descending) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
65862-0149-90 65862-0149 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Oct. 30, 2007 In Use
65862-0149-61 65862-0149 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral June 30, 2011 Oct. 25, 2011 In Use
65862-0149-30 65862-0149 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Oct. 30, 2007 In Use
65862-0149-05 65862-0149 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Oct. 30, 2007 In Use
65862-0149-01 65862-0149 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Oct. 30, 2007 In Use
65841-0744-30 65841-0744 Letrozole Letrozole 2.5 mg/1 Hormonal Therapy Aromatase Inhibitor Oral June 3, 2011 In Use
65841-0744-10 65841-0744 Letrozole Letrozole 2.5 mg/1 Hormonal Therapy Aromatase Inhibitor Oral June 3, 2011 In Use
65841-0744-06 65841-0744 Letrozole Letrozole 2.5 mg/1 Hormonal Therapy Aromatase Inhibitor Oral June 3, 2011 In Use
65841-0743-10 65841-0743 Anastrozole Anastrozole 1.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral June 27, 2010 In Use
65841-0743-06 65841-0743 Anastrozole Anastrozole 1.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral June 27, 2010 In Use
65841-0654-06 65841-0654 Bromocriptine Mesylate Bromocriptine Mesylate 5.0 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Jan. 23, 2009 In Use
65841-0654-01 65841-0654 Bromocriptine Mesylate Bromocriptine Mesylate 5.0 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Jan. 23, 2009 In Use
65841-0613-30 65841-0613 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 6, 2009 In Use
65841-0613-10 65841-0613 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 6, 2009 In Use
65841-0613-06 65841-0613 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 6, 2009 In Use
65841-0613-05 65841-0613 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 6, 2009 In Use
65841-0613-01 65841-0613 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 6, 2009 In Use
65597-0511-28 65597-0511 QUIZARTINIB VANFLYTA 26.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral July 20, 2023 In Use
65597-0511-04 65597-0511 QUIZARTINIB VANFLYTA 26.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral July 20, 2023 In Use
65597-0504-28 65597-0504 QUIZARTINIB VANFLYTA 17.7 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral July 20, 2023 In Use
65597-0504-04 65597-0504 QUIZARTINIB VANFLYTA 17.7 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral July 20, 2023 In Use
65597-0407-28 65597-0407 Pexidartinib hydrochloride Turalio 125.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor CSF1R, KIT, FLT3 Oral Feb. 1, 2023 In Use
65597-0407-20 65597-0407 Pexidartinib hydrochloride Turalio 125.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor CSF1R, KIT, FLT3 Oral Feb. 1, 2023 In Use
65597-0406-01 65597-0406 fam-trastuzumab deruxtecan-nxki Enhertu 100.0 mg/5mL Immunotherapy Drug Antibody Conjugate Topoisomerase I Inhibitor Intravenous Dec. 20, 2019 In Use
65597-0402-28 65597-0402 pexidartinib Turalio 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor CSF1R, KIT, FLT3 Oral Aug. 2, 2019 Jan. 31, 2024 No Longer Used
65597-0402-20 65597-0402 pexidartinib Turalio 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor CSF1R, KIT, FLT3 Oral Aug. 2, 2019 Jan. 31, 2024 No Longer Used
65580-0251-01 65580-0251 Prednisolone Sodium Phosphate Prednisolone Sodium Phosphate Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb. 11, 2002 March 13, 2013 No Longer Used
65483-0116-07 65483-0116 Aldesleukin Proleukin 1.1 mg/mL Immunotherapy Cytokine Interleukin-2 Intravenous May 5, 1992 In Use
65293-0374-20 65293-0374 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov. 18, 2009 In Use
65293-0374-01 65293-0374 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov. 18, 2009 In Use
65293-0373-25 65293-0373 ONDANSETRON HYDROCHLORIDE Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov. 18, 2009 Jan. 31, 2015 In Use
65293-0373-02 65293-0373 ONDANSETRON HYDROCHLORIDE Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov. 18, 2009 Jan. 31, 2015 In Use
65219-0568-00 65219-0568 MITOMYCIN MITOMYCIN 40.0 mg/80mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Jan. 15, 2023 In Use
65219-0566-20 65219-0566 MITOMYCIN MITOMYCIN 20.0 mg/40mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Jan. 15, 2023 In Use
65219-0564-20 65219-0564 MITOMYCIN MITOMYCIN 5.0 mg/10mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Jan. 15, 2023 In Use
65219-0552-02 65219-0552 Pralatrexate Pralatrexate 40.0 mg/2mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Nov. 15, 2022 In Use
65219-0550-01 65219-0550 Pralatrexate Pralatrexate 20.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Nov. 15, 2022 In Use
65219-0371-10 65219-0371 pegflilgrastim-fpgk STIMUFEND 6.0 mg/.6mL Ancillary Therapy Immunostimulant Granulocyte colony stimulating factor Subcutaneous Oct. 6, 2022 In Use
65219-0359-50 65219-0359 CISPLATIN Cisplatin 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 1, 2023 In Use
65219-0284-12 65219-0284 PLERIXAFOR Plerixafor 24.0 mg/1.2mL Ancillary Therapy Immunostimulant Stem Cell Mobilizer Subcutaneous June 22, 2023 In Use
65219-0200-05 65219-0200 Temsirolimus Temsirolimus Chemotherapy Enzyme Inhibitor mTOR Intravenous Nov. 20, 2020 In Use
65219-0160-10 65219-0160 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous Nov. 11, 2019 In Use
65219-0135-20 65219-0135 Cyclophosphamide Cyclophosphamide 500.0 mg/25mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral Nov. 17, 2023 In Use
65219-0133-20 65219-0133 Cyclophosphamide Cyclophosphamide 2.0 g/100mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 17, 2023 In Use
65219-0131-20 65219-0131 Cyclophosphamide Cyclophosphamide 1.0 g/50mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 17, 2023 In Use
65219-0029-20 65219-0029 Thiotepa Thiotepa 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine Intracavitary, Intravenous, Intravesical April 11, 2022 In Use
65174-0880-50 65174-0880 Sodium Iodide I 131 HICON 1000.0 mCi/mL Chemotherapy Radiopharmaceutical Iodine 131 Oral April 7, 2003 In Use
65174-0880-25 65174-0880 Sodium Iodide I 131 HICON 1000.0 mCi/mL Chemotherapy Radiopharmaceutical Iodine 131 Oral April 7, 2003 In Use
65174-0880-00 65174-0880 Sodium Iodide I 131 HICON 1000.0 mCi/mL Chemotherapy Radiopharmaceutical Iodine 131 Oral April 7, 2003 In Use
65162-0844-50 65162-0844 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 10, 2017 Feb. 1, 2024 No Longer Used

Found 10,000 results in 9 millisecondsExport these results